FibroBiologics, Inc.
FBLG evidence brief
What we can confirm
- Market Cap:
- $10.7M
What it means
What to watch
Prepared research question
What matters most for FBLG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FBLG
FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company developing fibroblast-based therapeutics for chronic diseases, with a lead program in diabetic foot ulcers and a large patent portfolio.
Key risk: Early-stage pipeline
Market Cap
$10.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for FibroBiologics, Inc..
FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company developing fibroblast-based therapeutics for chronic diseases, with a lead program in diabetic foot ulcers and a large patent portfolio.
- Clinical-stage biotech with 270+ patents issued and pending focused on fibroblast-derived therapies [news · published 2026-08-27].
- Lead program CYWC628 (human dermal fibroblast spheroids) is in a Phase 1/2 trial for diabetic foot ulcers, with first patient dosed June 2026 [news · published 2026-06-16].
- Cash & equivalents of $3.5M as of 2026-06-30 [sec].
- Net income of -$4.1M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $4.6M as of 2026-06-30 [sec].
What works
- Large intellectual property portfolio of 270+ patents provides a broad foundation for multiple therapeutic programs [news · published 2026-08-27].
- Successful manufacturing of multiple batches of CYWC628 drug product suggests operational capability in producing fibroblast-based spheroids [news · published 2026-07-07].
- Company expects existing drug supply to suffice for the ongoing Phase 1/2 trial, potentially leading to cost savings [news · published 2026-07-07].
What to weigh
- Limited cash position of $3.5M as of 2026-06-30 may constrain operations without additional financing [sec].
- Net loss of $4.1M for the period ending 2026-06-30 indicates ongoing cash burn [sec].
- All programs are in early clinical or preclinical stages; no approved products or revenue from product sales [news · published 2026-08-27].
From the filings
Quoted directly from source documents.
Company has over 270 patents
“270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials”
News · August 27, 2026
First patient dosed in Phase 1/2 DFU trial
“FibroBiologics Doses First Participant In Its Phase 1/2 Clinical Study Of CYWC628 To Treat Diabetic Foot Ulcers”
News · June 16, 2026
Catalyst timeline
- 2026-06-01 · Phase 2 Start for CYWC628 — A prospective, randomized, controlled trial evaluating CYWC628 for refractory diabetic foot ulcers compared with standard of care.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — All programs are in Phase 1/2 or earlier; no approved products or commercial revenue [news · published 2026-08-27].
- Cash runway — Cash of $3.5M with net loss of $4.1M may require near-term financing [sec].
- Single lead program — Primary focus on CYWC628 for DFU; pipeline diversification still preclinical [news · published 2026-08-27].
What to watch
- Progress of Phase 1/2 CYWC628 trial for diabetic foot ulcers, including enrollment and safety data [news · published 2026-08-27].
- Financial updates, particularly cash position and any new financing rounds [sec].
- Advancement of preclinical programs (CYPS317 for psoriasis, CYMS101 for multiple sclerosis) toward IND filings [news · published 2025-11-01].
Sources: Catalysts · News · Generated October 11, 2026 · How we verify sources →
Run FibroBiologics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FibroBiologics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$290K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 67,665 | $89K |
| fund evaluation group, llc | 51,794 | $68K |
| geode capital management, llc | 29,609 | $39K |
| blackrock, inc. | 24,647 | $33K |
| cascade financial partners, llc | 16,428 | $22K |
| renaissance technologies llc | 15,997 | $21K |
| vanguard fiduciary trust co | 6,380 | $8K |
| ubs group ag | 5,721 | $8K |
| vanguard global advisers, llc | 536 | $708 |
| tower research capital llc (trc) | 460 | $607 |
Showing top 10 of 17 institutional holders of FibroBiologics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 2.4%
- Days to cover
- 0.1
- Shares short
- 99,974
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FBLG short interestGovernance
Frequently asked questions
What is the AI investment thesis for FibroBiologics, Inc.?
FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company developing fibroblast-based therapeutics for chronic diseases, with a lead program in diabetic foot ulcers and a large patent portfolio.
Who is the CEO of FibroBiologics, Inc.?
Mr. Peter O'Heeron is the chief executive officer of FibroBiologics, Inc. (FBLG).
Where is FibroBiologics, Inc. headquartered?
FibroBiologics, Inc. (FBLG) is headquartered in Houston, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.